Theripio Innovations (the startup)

Theripio Innovations is the startup company founded by Dr. Christopher Cowan at MUSC to commercialize the MEF2C RNA therapeutic platform. In drug development, when academic researchers develop a promising therapy, they typically form a startup company to handle the transition from lab to clinic. This company will: - Handle intellectual property and patent filing - Seek additional funding (venture capital, partnerships) - Run clinical trials - Navigate FDA approval - Eventually bring the drug to market Why this matters: The formation of a dedicated startup is a major milestone. It means the research has progressed from "academic curiosity" to "commercially viable therapeutic program." Startups have a track record of being more agile and faster than academic institutions in moving therapies forward.